Future Prospects: Key Trends Shaping the Corticosteroids Market Until 2029

The corticosteroids market is on a promising trajectory, driven by several significant factors that are shaping its expansion. This sector is witnessing advances due to increasing health challenges, new product developments, and strategic business moves by key players. Let's explore the current market size, leading companies, emerging trends, and important segments that define this vital pharmaceutical field.

Corticosteroids Market Size and Forecast Through 2030
The corticosteroids sector is anticipated to experience substantial growth in the coming years. By 2030, the market value is projected to reach $8.34 billion, expanding at a compound annual growth rate (CAGR) of 7.1%. This upward trend is fueled by a rising prevalence of autoimmune and respiratory diseases, the introduction of safer steroid formulations, an aging global population, improved healthcare access in developing countries, and increased research investment in corticosteroids. Key developments expected to influence the market include more targeted corticosteroid products, therapies with lower doses and shorter durations, growth in topical and inhaled corticosteroid usage, combination treatments with bronchodilators, and broader application in acute respiratory care.

Download a free sample of the corticosteroids market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2832&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players in the Corticosteroids Industry
The corticosteroids market features a number of prominent corporations that maintain a strong presence globally. These include McKesson Corporation, Pfizer Inc., Johnson and Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals Ltd., LEO Pharma A/S, Glenmark Pharmaceuticals Ltd., Wockhardt Limited, Allergan plc, and Hikma Pharmaceuticals plc.

A notable recent development occurred in June 2024, when Sun Pharmaceutical Industries Ltd., a specialty generic pharmaceutical company based in India, acquired Taro Pharmaceutical Industries Ltd. for an undisclosed price. This acquisition aims to bolster Sun Pharma's market share, particularly in off-patent pharmaceuticals, prescription medicines, and over-the-counter products. Taro Pharmaceutical Industries Ltd., based in Israel, specializes in research-based pharmaceutical manufacturing, including corticosteroid products.

View the full corticosteroids market report:
https://www.thebusinessresearchcompany.com/report/corticosteroid-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Key Drivers Behind Growth in the Corticosteroids Market
One important factor driving the corticosteroids market is the rising demand for medications that address autoimmune and respiratory conditions worldwide. As these health issues become more prevalent, more patients require effective therapies, pushing market growth forward.

Another significant influence is the advancement of safer and more targeted steroid formulations. These innovations improve treatment efficacy while minimizing side effects, attracting both healthcare providers and patients. Enhanced accessibility to healthcare services in emerging markets also plays a crucial role in expanding the reach of corticosteroid therapies.

Emerging Trends Reshaping the Corticosteroids Market
Pharmaceutical companies are focusing heavily on developing innovative products like rescue medications that provide quick relief for acute symptoms. These drugs serve a critical need in managing sudden exacerbations of chronic diseases and expanding treatment options.

For example, in January 2023, AstraZeneca PLC, a UK-based firm, secured FDA approval for Airsupra (albuterol/budesonide), marking a breakthrough as the first-in-class pressurized metered-dose inhaler (pMDI) combining a short-acting beta2-agonist (SABA) with an inhaled corticosteroid (ICS). This fixed-dose rescue inhaler is designed for adults 18 and older and offers on-demand relief and prevention of bronchoconstriction, while also reducing asthma exacerbation risks. AstraZeneca is developing this product in partnership with Avillion, and it is currently available in the U.S.

The increasing adoption of combination therapies involving corticosteroids and bronchodilators is another trend gaining momentum. These treatments improve patient outcomes by providing comprehensive respiratory care through multiple mechanisms.

Breakdown of the Corticosteroids Market by Product, Application, and End User
This market report segments corticosteroids into major categories for better understanding:
1) Product Type:
- Glucocorticoids
- Mineralocorticoids

2) Application Areas:
- Skin Allergies
- Rheumatology Indications
- Endocrinology
- Acute Respiratory Diseases
- Other Applications

3) End Users:
- Hospitals
- Clinics
- Research Institutes
- Other End Users

Further sub-segments under glucocorticoids include Hydrocortisone, Prednisone, Dexamethasone, Methylprednisolone, Triamcinolone, Betamethasone, and others. Mineralocorticoids cover Fludrocortisone, Aldosterone, and additional compounds. This detailed classification helps pinpoint areas of highest demand and innovation within the corticosteroids sector.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.